Abstract 2155: One year clinical outcomes associated with the use of a Zotarolimus eluting stent: A Single-Center Canadian Experience

TL;DRAbstract

Background: The use of drug eluting stents (DES) has improved clinical and angiographic outcomes by reducing the need for target vessel revascularization (TVR). Clinical outcomes associated with the use a novel DES, the Zotarolimus-eluting phosphorylcholine-coated (Endeavor®) stent are less well established. A randomized clinical trial examining the benefits of the Endeavor® stent the rates of target vessel revascularization (TVR), target lesion revascularization (TLR) and stent thrombosis (ST) rates at 9 months in a select “study population” were reported as 7.9%, 4.6% and 0.5% respectively. These studies examined the outcomes of the Endeavor® stents in patients with single and non-complex lesions, while excluding patients with Acute Coronary Syndrome (ACS), Left Main (LM) lesions or In-stent restenosis (ISR). The outcomes of the Endeavor® stents in a “real-world” population have not been studied. The objective of this study was to evaluate the safety and efficacy of Endeavor® stents

Chat with Paper

AI Agents for this Paper